Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development
March 28 2023 - 7:05AM
Business Wire
Dr. Romano will succeed Dr. Giles Campion, CMO
and Head of R&D, following his retirement by year-end
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the
Company”), an experienced and innovative biotechnology company
committed to transforming people’s lives by silencing diseases
through precision engineered medicines, today announced the
appointment of Steven Romano, MD, as incoming Chief Medical Officer
and Head of Research and Development. Dr. Romano will join Silence
on April 1, 2023, and work alongside Giles Campion, MD, current CMO
and Head of R&D at Silence, to ensure an efficient and smooth
transition for Dr. Campion’s retirement by year-end.
Dr. Romano has served as non-executive director of the Silence
Board since July 2019 following the Company’s siRNA collaboration
with Mallinckrodt plc for complement-mediated diseases. Since then,
Dr. Romano has played a key role overseeing the company’s
complement portfolio. In a press release issued this morning,
Silence announced that it was buying back two of its siRNA assets
from Mallinckrodt.
“Giles has been instrumental in leading our R&D efforts to
get Silence to where it is today – a clinical stage company
advancing multiple programs – and we are grateful for his continued
dedication to the company,” said Craig Tooman, President and CEO of
Silence. “We are very pleased to welcome Steven Romano to our
executive team in this crucial role as we enter the next chapter of
innovation and growth at Silence. His extensive experience
overseeing research and development, regulatory and medical affairs
make him the ideal leader to advance our clinical activities and
pursue new opportunities to maximize our mRNAi GOLD™ platform
technology.”
“Being a member of the Silence Board since July 2019, I’ve
developed a deep understanding and appreciation for the company’s
siRNA platform technology to address a broad range of genetic
diseases,” said Steven Romano, MD. “I’m honored to assume the
leadership of Silence’s R&D organization and look forward to
building on this strong momentum to help bring transformative
medicines to people around the world.”
Dr. Romano is also a board-certified psychiatrist with more than
25 years of experience in the pharmaceutical industry, including 16
years at Pfizer. Most recently, he served as executive vice
president and chief scientific officer at Mallinckrodt and was
responsible for research and development, medical affairs, health
economics and outcomes research, safety, pharmacovigilance and
regulatory affairs functions. At Pfizer, Dr. Romano served in a
series of senior roles, including Senior Vice President, Head,
Global Medicines Development, Global Innovative Pharmaceuticals
Business. Before Pfizer, he spent four years at Eli Lilly
performing clinical research. Dr. Romano received his bachelor’s
degree in biology from Washington University in St. Louis and his
medical degree from the University of Missouri-Columbia. He
completed his residency and fellowship at New York Hospital-Cornell
Medical Center, where he then served on the medical school faculty
for six years.
About Silence Therapeutics Silence Therapeutics is
developing a new generation of medicines by harnessing the body’s
natural mechanism of RNA interference, or RNAi, to inhibit the
expression of specific target genes thought to play a role in the
pathology of diseases with significant unmet need. Silence’s
proprietary mRNAi GOLD™ platform can be used to create siRNAs
(short interfering RNAs) that precisely target and silence
disease-associated genes in the liver, which represents a
substantial opportunity. Silence’s wholly owned product candidates
include SLN360 designed to address the high and prevalent unmet
medical need in reducing cardiovascular risk in people born with
high levels of lipoprotein(a) and SLN124 designed to address rare
hematological diseases. Silence also maintains ongoing research and
development collaborations with AstraZeneca, Mallinckrodt
Pharmaceuticals and Hansoh Pharma, among others. For more
information, please visit
https://www.silence-therapeutics.com/.
Forward-Looking Statements Certain statements made in
this announcement are forward-looking statements within the meaning
of the U.S. Private Securities Litigation Reform Act of 1995 and
other securities laws, including with respect to the Company’s
clinical and commercial prospects, regulatory approvals of the
Company’s product candidates, potential partnerships or
collaborations or payments under new and existing collaborations,
the initiation or completion of the Company’s clinical trials and
the anticipated timing or outcomes of data reports from the
Company’s clinical trials. These forward-looking statements are not
historical facts but rather are based on the Company's current
assumptions, beliefs, expectations, estimates and projections about
its industry. Words such as 'anticipates,' 'expects,' 'intends,'
'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions
are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject
to known and unknown risks, uncertainties, and other factors, some
of which are beyond the Company's control, are difficult to
predict, and could cause actual results to differ materially from
those expressed or forecasted in the forward-looking statements,
including those risks identified in the Company’s most recent
Admission Document and its Annual Report on Form 20-F filed with
the U.S. Securities and Exchange Commission (the “SEC”) on March
15, 2023. The Company cautions security holders and prospective
security holders not to place undue reliance on these
forward-looking statements, which reflect the view of the Company
only as of the date of this announcement. The forward-looking
statements made in this announcement relate only to events as of
the date on which the statements are made. The Company will not
undertake any obligation to release publicly any revisions or
updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230328005336/en/
Enquiries:
Silence Therapeutics plc Gem Hopkins, VP, Head of IR and
Corporate Communications ir@silence-therapeutics.com
Tel: +1 (646) 637-3208
Silence Therapeutics (NASDAQ:SLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Silence Therapeutics (NASDAQ:SLN)
Historical Stock Chart
From Jul 2023 to Jul 2024